{"id":"W4401878668","doi":"10.1016/s2152-2650(24)00573-1","title":"Interim Results From ASSURE: A Phase 3b Safety Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukemia","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Interim; Chronic lymphocytic leukemia; Interim analysis; Oncology; Internal medicine; Leukemia; Clinical trial; Law","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003654757,0.001020408,0.001949882,0.0004048536,0.0006508881,0.001558204,0.0006100482,0.001060296,0.005204828],"category_scores_gemma":[0.00276621,0.0003425789,0.002414797,0.0004135451,0.0005977297,0.0009257712,0.0003450411,0.003076545,0.001276728],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009419234,"about_ca_system_score_gemma":0.001570714,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000896824,"about_ca_topic_score_gemma":0.002509638,"domain_scores_codex":[0.998987,0.0005713377,0.00004651767,0.0000917852,0.0001309795,0.0001723357],"domain_scores_gemma":[0.9983742,0.0005338417,0.000325214,0.0001605902,0.0001898404,0.000416204],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5886427,0.01484201,0.02063027,0.001974693,0.006117096,0.0004818684,0.0004503668,0.005766168,0.02854319,0.001979251,0.05823411,0.2723383],"study_design_scores_gemma":[0.5517487,0.306577,0.0640857,0.0002562164,0.003679059,0.001692538,0.0002339652,0.004714448,0.01118677,0.003242522,0.05246469,0.0001184919],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9473335,0.01325413,0.003823319,0.002926242,0.0005305731,0.002466038,0.01179572,0.0008750796,0.01699541],"genre_scores_gemma":[0.970411,0.003173407,0.00354408,0.004357609,0.0004630573,0.002430005,0.01048518,0.0001639616,0.004971745],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005204828,"threshold_uncertainty_score":0.01932847,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03560786394838119,"score_gpt":0.3675414112304161,"score_spread":0.3319335472820349,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}